SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is trending as investors react to the company's recent leadership transition, the appointment of former Pfizer CMO Dr. Freda Lewis-Hall to its board, and anticipation surrounding upcoming Phase 2 data for its GAD program. The community remains polarized, with some highlighting the company's robust IP portfolio and institutional accumulation, while others express concerns over the stock's historical volatility and ongoing cash burn.

Beamable Network is a decentralized compute infrastructure designed to power real games and digital experiences. Built by the team behind Beamable Inc.—a backend platform already serving over 95 live games—the network transforms compute into an open, tokenized marketplace. By combining distributed node operators, verifiable workloads, and blockchain incentives, Beamable Network provides scalable, cost-efficient infrastructure for any compute applications without dependence on centralized cloud providers.

Beamable Network Token

Beamable Network Token is experiencing heightened community interest driven by rapid price volatility and significant order book activity. Traders are actively tracking potential breakout patterns while debating the sustainability of the current momentum amid broader market speculation.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Rigel Pharmaceuticals is trending as investors monitor significant short interest and volatility following recent ASH presentations and potential M&A speculation. The community is actively discussing the company's transition into a profitable commercial entity while awaiting further catalysts like potential pipeline updates or partnership news.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is facing downward pressure following significant insider selling by the CEO, sparking community frustration regarding management's long-term strategy and a desire for an acquisition. Despite these concerns, investors remain focused on the potential of the Casgevy commercial rollout and upcoming clinical data readouts across the firm's gene-editing pipeline.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is generating significant community conversation as traders weigh its consolidation patterns against historical volatility and speculation surrounding potential integration with major social platforms. While some investors remain cautious due to sluggish price action compared to other assets, many are actively debating if it is currently positioned for a breakout or a further downturn.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as investors focus on a major upcoming Phase 3 data readout for its hereditary angioedema therapy, which has sparked intense debate over the stock's high short interest and potential for a squeeze. While recent clinical hold removals have bolstered optimism regarding the company's gene-editing platform, community discussion remains polarized by volatility, valuation concerns, and the impact of the biotech sector's broader market environment.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disney is facing intense scrutiny as a leadership transition to incoming CEO Josh D'Amaro highlights ongoing concerns regarding operational efficiency, content performance, and market stagnation. The community is actively debating the stock's long-term viability, weighing the company's streaming profitability and park demand against frustrations over persistent share price underperformance and polarizing creative strategies.

ProShares Trust II - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is seeing heavy activity as traders speculate on the impact of heightened Middle East tensions and potential energy supply disruptions on natural gas markets. The community is actively debating the reliability of recent geopolitical news versus underlying supply-demand fundamentals, with many focusing on the impact of seasonal shoulder-month demand and the inherent decay mechanics of leveraged ETFs.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Direxion Daily Semiconductor Bear 3X Shares is facing immense downward pressure as the semiconductor sector continues a historic, parabolic rally that has pushed major chip stocks to record-breaking streaks. Investors are actively debating whether this movement represents an unsustainable bubble or a new super-cycle, with many using the fund as a high-risk hedge against further sector expansion.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgen is seeing heavy market engagement as investors weigh strong Q2 earnings, which featured double-digit volume growth in key assets like Repatha and Evenity, against concerns over pricing pressures and patent cliffs. The community is actively discussing Amgens competitive positioning in the high-stakes obesity pipeline alongside speculation regarding future M&A potential and the company's long-term manufacturing expansion strategy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

B. Metzler seel. Sohn & Co. AG Reduces Stock Position in Flowserve Corporation $FLS

B. Metzler seel. Sohn & Co. AG reduced its position in shares of Flowserve Corporation (NYSE:FLS - Free Report) by 29.7% in the fourth quarter, according to the company in its most recent disclosure...

Flowserve (NYSE:FLS) Lowered to "Hold" Rating by Wall Street Zen

Wall Street Zen lowered shares of Flowserve from a "buy" rating to a "hold" rating in a research note on Saturday...

Paradice Investment Management LLC Grows Stake in Flowserve Corporation $FLS

Paradice Investment Management LLC increased its position in Flowserve Corporation (NYSE:FLS - Free Report) by 52.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 516,510 shares of the industrial products...

Dover Q1 Earnings Beat Estimates, Rise Y/Y on Solid Demand 

DOV tops Q1 estimates as strong demand, rising bookings, and solid segment growth drive double-digit earnings and revenue gains.

Peregrine Capital Management LLC Sells 15,951 Shares of Flowserve Corporation $FLS

Peregrine Capital Management LLC decreased its holdings in shares of Flowserve Corporation (NYSE:FLS - Free Report) by 7.0% in the 4th quarter, according to the company in its most recent disclosure...

Parker-Hannifin (PH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Parker-Hannifin (PH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Flowserve Corporation $FLS Shares Sold by Cwm LLC

Cwm LLC lessened its holdings in shares of Flowserve Corporation (NYSE:FLS - Free Report) by 27.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 53,033 shares of the industrial products company's sto...

Flowserve (FLS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Flowserve (FLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

US Nuclear Renaissance Finally Starts...? TNC Plans New South Carolina Reactor

US Nuclear Renaissance Finally Starts...? TNC Plans New South Carolina Reactor The Nuclear Co. (TNC), a startup that emerged from stealth in 2024 as America's full-stack nuclear project integrator...

Flowserve (FLS) Moves 7.7% Higher: Will This Strength Last?

Flowserve (FLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Flowserve Corp. engages in the manufacture and provision of aftermarket service for comprehensive flow control systems. It operates through Flowserve Pumps Division and Flow Control Division segments. The Flowserve Pumps Division designs, manufactures, pretests, and distributes pumps, pre-configured industrial pumps, pump systems, mechanical seals, auxiliary systems and replacement parts, and related services. The Flow Control Division segment designs, manufactures, and distributes a broad portfolio of engineered-to-order and configured-to-order isolation valves, control valves, valve automation products and related services and equipment. The company was founded in 1790 and is headquartered in Irving, TX.

FLS
Flowserve Corp.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest FLS News

FLSFlowserve Corp.